Why Buyout Giants Are Investing in Each Other's Deals
More buyout shops are raising money to buy pieces of companies that other private equity firms can't or don't want to completely offload. The assets are landing in so-called continuation funds, which allow old investors to cash out and give new investors an opportunity to cash in.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
37 minutes ago
- Yahoo
VeriSign (VRSN) Announced Increased Earnings
In July 2025, VeriSign expanded its buyback authorization and announced increased earnings, alongside a declared cash dividend. Despite these positive developments, the company's share price declined by 5.90% over the past month. This decline coincided with a broader market downturn, driven by global tariff uncertainties and disappointing job data. While VeriSign's solid financial results might have typically buoyed investor confidence, the market context placed downward pressure on its stock. The company's follow-on equity offering also added complexity to its share dynamics over this period, contributing to a challenging market performance. Every company has risks, and we've spotted 3 warning signs for VeriSign (of which 1 shouldn't be ignored!) you should know about. Rare earth metals are the new gold rush. Find out which 25 stocks are leading the charge. VeriSign's recent expansion of its buyback authorization and earnings increase, juxtaposed with a share price decline of 5.90% during July, showcases the complexity of market dynamics. This decline coincided with external market pressures like global tariff uncertainties and disappointing job data. Despite these pressures, VeriSign's solid financial results and strategic initiatives may support long-term growth. Notably, in the last year, VeriSign's total return, including dividends, was 41.76%, highlighting its strong performance over a broader timeline despite recent challenges. Comparatively, over the past year, VeriSign outperformed the US market, which returned 16.8%, and also exceeded the US IT industry with its 24.5% return. The company's ongoing initiatives, such as improving domain registration trends and marketing strategies, could positively impact revenue growth, while the introduction of dividends reflects financial stability that could enhance earnings forecasts. VeriSign's current share price of US$265.37 is below the analyst consensus price target of US$309.0, indicating a 16.44% discount, which resonates with the potential for value growth should the company's revenue and earnings forecasts materialize as expected. In light of our recent valuation report, it seems possible that VeriSign is trading beyond its estimated value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include VRSN. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
37 minutes ago
- Yahoo
CRISPR Therapeutics (CRSP) Sees 47% Price Increase Over Last Quarter
CRISPR Therapeutics recently announced significant developments in its in vivo cardiovascular disease programs, notably CTX310 and CTX320, which may have contributed to the company's 47% share price increase over the last quarter. The company's inclusion in multiple indices further enhances its market presence, potentially impacting investor interest positively. Meanwhile, CRISPR reported a net loss in its Q1 earnings, although revenue increased year-over-year. Despite a volatile market backdrop, characterized by declining major indices due to weak job reports and tariff concerns, CRISPR's advancements in therapeutic programs and strategic index additions contrasted against broader market movements. We've spotted 1 risk for CRISPR Therapeutics you should be aware of. Uncover the next big thing with financially sound penny stocks that balance risk and reward. Over the past year, CRISPR Therapeutics reported a total shareholder return of 9.74%. While the company's shares outperformed the US Biotechs industry, which returned a decline of 8.4% over the same period, it lagged behind the broader US Market's 17.7% return. The favorable performance relative to its industry can be linked to its strategic advancements in cardiovascular disease programs and inclusion in various Russell indices. The recent developments highlighted in the introduction, particularly the positive updates in CRISPR's cardiovascular programs and index additions, could potentially influence expectations around future revenue and earnings. Analysts forecast strong revenue growth of 57.3% annually, despite the company's forecast to remain unprofitable over the next three years. Meanwhile, with the current share price at $56.09, the market seems to discount the consensus analyst price target of $80.91, reflecting a substantial perceived upside potential in the stock. This price movement suggests that investors might see potential growth opportunities, even as the company navigates its profitability challenges. The valuation report we've compiled suggests that CRISPR Therapeutics' current price could be quite moderate. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include CRSP. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
an hour ago
- Yahoo
Market moves past trade deal euphoria—Morgan Stanley dives into what comes next
-- Trade war fears may no longer be dominating the spotlight, but beneath the surface, the global trade regime remains a moving target, with new deals, shifting deadlines, and policy lags fueling persistent uncertainty for businesses and investors alike. But as markets celebrate recent U.S. deals with the EU and Japan, the tariff story is far from over—a reality set to linger well into year-end and beyond, Morgan Stanley analysts warned in a recent note. "Tariffs are likely to remain a moving target. Deals that have been announced lack clarity or legal foundations, making it hard to assess their longevity," Morgan Stanley analysts said, warning that announced agreements often 'lack a legal structure, legislative process, and sector details... raising key questions, especially for businesses trying to invest' Baseline Trajectory: Higher but Volatile Tariffs into Year-End Morgan Stanley's expects a 'steady baseline of ~10-15% tariffs,' with higher rates reserved for China (potentially 20-45%). The analysts stress the volatility and execution risks remain as recent headline agreements remain 'difficult to implement and track.' 'Trade policy uncertainty in the aggregate is still high, with the potential for future frictions as these agreements are difficult to implement and track,' they added. Current Tariff Landscape: Hard to Pin Down Despite a flurry of deals, 'the post-August tariff landscape remains broadly consistent with our base case. Though, we caution that tariff levels remain difficult to pin down with precision because of volatility in import shares, compliance rates under USMCA, and the inherent lag in shipping data,' The EU deal, in particular, 'seems to have raised tariff levels from ~10% to ~15%, contributing as much as 2 percentage points to the overall tariff rate on US imports,' especially as pharma and semis lose exemptions. Tariffs Showing Up in Data—With a Lag The actual impact of tariffs is only just beginning to filter into the numbers. May's U.S. import data reflected an effective tariff rate of just 8.3%, but analysts expect 'convergence in June and July to a mid-teens effective tariff rate' as shipping delays and in-transit exemptions expire. 'We did see very clear signs of tariff-driven inflation across most goods' in the June CPI print, and Morgan Stanley expects 'tariffs to result in up to 1 percentage point level shift in prices in the coming months before subsiding as demand softens in reaction' Supply Chains Scramble in Real Time Companies aren't waiting for the dust to settle. Morgan Stanley said, pointing to material shift in supply chains to Vietnam and India. 'Material shifts to Vietnam and India are visible in recent months' across electronics supply chains, as firms react to changing tariff regimes. China's share of U.S. imports slumped to just 7.7% in May from 13.7% in 2024, but could rebound as embargo-level tariffs are relaxed. Tariffs on Mexico and Canada, meanwhile, have been lower than expected at 4.3% and 1.9%, respectively; this is likely due to a "combination of unexpectedly high USMCA compliance, significant US content in autos, and possibly lenient enforcement.' Inventory Frontloading: Not as Widespread as Feared Front-loading effects, meanwhile, were more targeted than broad-based. 'Roughly 80% of the increase in Q1 imports was driven by just seven HS6 categories including gold, pharmaceuticals, and AI-related goods... Excluding these, the cumulative excess imports compared to 2024 levels amounted to less than 2% of annual imports,' the analysts found. By May, as tariffs took hold, overall import volumes fell 5%. Sector-Specific Winners—and Losers Sectors are experiencing varying levels of impact from tariffs. 'Tariffs were highest in sectors like Fabricated Metal Products (Section 232 tariffs) and Textiles and May rates remained elevated at ~24% and ~20%, respectively. These sectors, however, account for a relatively small share of total imports. In contrast, high-volume categories such as Computers & Electronics, Chemicals & Pharmaceuticals, and fuels faced much lower tariff rates—under 10%—"dampening the aggregate inflationary impulse," the analysts added. The costs are falling squarely on U.S. importers, not exporters, and 'volumes are giving way rather than prices...[but] we are early in the tariff story, and things are very much in flux' Related articles Market moves past trade deal euphoria—Morgan Stanley dives into what comes next These Under-the-Radar Stocks Offer Better Risk-Reward Ratio Than Nvidia Surge of 50% since our AI selection, this chip giant still has great potential Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
